<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271219</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA15764-1</org_study_id>
    <secondary_id>R01DA015764</secondary_id>
    <secondary_id>R01DA15764-1</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00271219</nct_id>
  </id_info>
  <brief_title>RCT Comparing Methadone and Buprenorphine in Pregnant Women</brief_title>
  <official_title>Maternal Opioid Treatment: Human Experimental Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children born to women who abuse drugs have a high risk of being born with birth defects and
      developmental problems. Methadone is a drug that is commonly used for treating opioid
      dependence. However, its use by a pregnant woman can cause severe withdrawal symptoms in a
      newborn because of the prenatal exposure. The purpose of this study is to evaluate the
      effectiveness of buprenorphine, another drug, versus methadone in reducing withdrawal
      symptoms in children born to opioid-dependent women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who use drugs during pregnancy place their unborn children at high risk for being born
      addicted to drugs. Such children may also be born with birth defects and may experience
      learning and behavioral problems. Methadone, a synthetic narcotic, is commonly prescribed to
      treat opioid addiction. It may not be an optimal solution for opioid-dependent pregnant
      women, however, because a large percentage of children born to women taking methadone
      experience severe drug withdrawal symptoms at birth that often require medical treatment.
      Common opioid withdrawal symptoms, described as neonatal abstinence syndrome (NAS) in babies,
      include tremors, irritability, sleep problems, seizures, dehydration, and fever.
      Buprenorphine is a medication that has been approved to treat opioid dependence in
      individuals who are not pregnant but has not been approved for pregnant individuals. Past
      research has shown that use of buprenorphine in pregnant women results in improved birth
      outcomes over methadone. The purpose of this study is to evaluate the effectiveness of
      buprenorphine versus methadone at reducing opioid withdrawal symptoms in babies born to
      opioid-dependent women.

      This study will enroll opioid-dependent pregnant women who are 13 to 30 weeks pregnant and
      will follow each woman and her child throughout the pregnancy until 6 weeks postpartum. All
      participants will undergo an initial screening that will last several hours. Participants
      will then be randomly assigned to receive either methadone or buprenorphine on a daily basis,
      and will be required to visit the clinic each day to receive their medication. Outcome
      measurements will be assessed at weekly study visits throughout the pregnancy, and will
      include drug use, HIV risk behaviors, medication dose adequacy and safety, treatment
      retention, and psychosocial functioning. Urine samples will be collected 3 times a week, and
      blood will be drawn throughout the pregnancy for safety monitoring. Outcome measurements
      related to the baby will include head circumference measurement, length of hospital stay,
      severity and frequency of withdrawal symptoms, and amount of medication needed to control
      withdrawal symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Child's Head Circumference Measurement (Measured at Birth)</measure>
    <time_frame>birth</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Child's Length of Hospital Stay</measure>
    <time_frame>delivery until hospital discharge (min=2 days, max=79 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS)</measure>
    <time_frame>From birth until hospital discharge (min=4 days, max=10, depending on site)</time_frame>
    <description>Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Child's Peak Daily Total NAS Score</measure>
    <time_frame>minimum twice daily from birth until NAS no longer measured (min=10 days)</time_frame>
    <description>NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Morphine Sulfate That a Neonate Receives to Treat NAS</measure>
    <time_frame>Start of NAS treatment until discontinuation of NAS treatment (min=0 days, max=76 days)</time_frame>
    <description>Total amount in mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mother's Self-report of Drug Use (Measured Monthly by Time Line Follow Back)</measure>
    <time_frame>monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mother's HIV Risk Behaviors (Measured Monthly by Risk Behavior Assessment)</measure>
    <time_frame>monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mother's Measures of Dose Adequacy and Acceptance Over Time (Measured Weekly by Dose Adequacy Measure)</measure>
    <time_frame>from study entry until discontinuation or delivery (min=29 days, max=239 days)</time_frame>
    <description>Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mother's Psychosocial Functioning at Delivery as Measured by the Addiction Severity Index Psychosocial Index Score</measure>
    <time_frame>at delivery</time_frame>
    <description>The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Opioid Related Disorders</condition>
  <condition>Pregnancy</condition>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methadone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>daily oral dosing 20-140 mg</description>
    <arm_group_label>Methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>sl daily 2-32 mg</description>
    <arm_group_label>Buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current opioid dependence

          -  Current opioid use, as determined by a urine drug test

          -  Pregnant with a single child with a gestational age of 6 to 30 weeks, as determined by
             a sonogram

        Exclusion Criteria:

          -  Current medical condition that would make study participation dangerous, as determined
             by study physician

          -  Diagnosed with an acute, severe psychiatric illness

          -  Current SCID I-E module diagnosis of benzodiazepine or alcohol abuse

          -  Use of alcohol or benzodiazepines in the 30 days prior to study entry, as determined
             by the Addiction Severity Index

          -  Pending legal action that may prohibit or interfere with study participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendree E. Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2005</study_first_submitted>
  <study_first_submitted_qc>December 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2005</study_first_posted>
  <results_first_submitted>March 11, 2013</results_first_submitted>
  <results_first_submitted_qc>July 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2015</results_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Hendree E. Jones</investigator_full_name>
    <investigator_title>Professor, Dept of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>opiate addiction</keyword>
  <keyword>opiate dependence</keyword>
  <keyword>substance abuse</keyword>
  <keyword>addiction</keyword>
  <keyword>substance addiction</keyword>
  <keyword>pregnancy</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>methadone</keyword>
  <keyword>fetal</keyword>
  <keyword>neonatal</keyword>
  <keyword>post-partum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1074 Patients were screened for eligibility. 175 underwent randomization. 86 were assigned to receive buprenorphine. 58 of the patients assigned to buprenorphine completed the study. 89 were assigned to receive methadone. 73 of the patients assigned to methadone completed the study.</recruitment_details>
      <pre_assignment_details>Of the 1074 screened: 243 did not give consent. 656 were excluded for a variety of reasons ranging from an estimated gestation age outside the range, to impending legal issues, to multiple-fetus pregnancy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methadone</title>
          <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
        </group>
        <group group_id="P2">
          <title>Buprenorphine</title>
          <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methadone</title>
          <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
        </group>
        <group group_id="B2">
          <title>Buprenorphine</title>
          <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="0.7"/>
                    <measurement group_id="B2" value="25.3" spread="0.7"/>
                    <measurement group_id="B3" value="26.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Child's Head Circumference Measurement (Measured at Birth)</title>
        <time_frame>birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Child's Head Circumference Measurement (Measured at Birth)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="32.7" upper_limit="33.3"/>
                    <measurement group_id="O2" value="33.8" lower_limit="33.5" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Child's Length of Hospital Stay</title>
        <time_frame>delivery until hospital discharge (min=2 days, max=79 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Child's Length of Hospital Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="16" upper_limit="19"/>
                    <measurement group_id="O2" value="10.0" lower_limit="8.8" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS)</title>
        <description>Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death.</description>
        <time_frame>From birth until hospital discharge (min=4 days, max=10, depending on site)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS)</title>
          <description>Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Child's Peak Daily Total NAS Score</title>
        <description>NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal.</description>
        <time_frame>minimum twice daily from birth until NAS no longer measured (min=10 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Child's Peak Daily Total NAS Score</title>
          <description>NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal.</description>
          <units>Score on the scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="12.2" upper_limit="13.4"/>
                    <measurement group_id="O2" value="11.0" lower_limit="10.4" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Morphine Sulfate That a Neonate Receives to Treat NAS</title>
        <description>Total amount in mg</description>
        <time_frame>Start of NAS treatment until discontinuation of NAS treatment (min=0 days, max=76 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Morphine Sulfate That a Neonate Receives to Treat NAS</title>
          <description>Total amount in mg</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7.8" upper_limit="13"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.4" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mother's Self-report of Drug Use (Measured Monthly by Time Line Follow Back)</title>
        <time_frame>monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)</time_frame>
        <population>frequency of use during the course of the study was too low to estimate the parameter with sufficient accuracy</population>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mother's Self-report of Drug Use (Measured Monthly by Time Line Follow Back)</title>
          <population>frequency of use during the course of the study was too low to estimate the parameter with sufficient accuracy</population>
          <units>percentage of drug use</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">frequency of use during the course of the study was too low to estimate the parameter with sufficient accuracy</measurement>
                    <measurement group_id="O2" value="NA">frequency of use during the course of the study was too low to estimate the parameter with sufficient accuracy</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mother's HIV Risk Behaviors (Measured Monthly by Risk Behavior Assessment)</title>
        <time_frame>monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)</time_frame>
        <population>frequency of occurrence too low to be estimated with accuracy</population>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mother's HIV Risk Behaviors (Measured Monthly by Risk Behavior Assessment)</title>
          <population>frequency of occurrence too low to be estimated with accuracy</population>
          <units>percentage of HIV risk behaviors</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">frequency of occurrence too low to be estimated with accuracy</measurement>
                    <measurement group_id="O2" value="NA">frequency of occurrence too low to be estimated with accuracy</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mother's Measures of Dose Adequacy and Acceptance Over Time (Measured Weekly by Dose Adequacy Measure)</title>
        <description>Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study.</description>
        <time_frame>from study entry until discontinuation or delivery (min=29 days, max=239 days)</time_frame>
        <population>intra-subject variability in dosing (typically 1 dose) over course of the trial was too small to estimate the parameter of interest with sufficient accuracy</population>
        <group_list>
          <group group_id="O1">
            <title>A Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>B Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mother's Measures of Dose Adequacy and Acceptance Over Time (Measured Weekly by Dose Adequacy Measure)</title>
          <description>Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study.</description>
          <population>intra-subject variability in dosing (typically 1 dose) over course of the trial was too small to estimate the parameter of interest with sufficient accuracy</population>
          <units>dose increase per trimester</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">intra-subject variability in dosing (typically 1 dose) over course of the trial was too small to estimate the parameter of interest with sufficient accuracy</measurement>
                    <measurement group_id="O2" value="NA">intra-subject variability in dosing (typically 1 dose) over course of the trial was too small to estimate the parameter of interest with sufficient accuracy</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mother's Psychosocial Functioning at Delivery as Measured by the Addiction Severity Index Psychosocial Index Score</title>
        <description>The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study.</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone</title>
            <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine</title>
            <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mother's Psychosocial Functioning at Delivery as Measured by the Addiction Severity Index Psychosocial Index Score</title>
          <description>The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study.</description>
          <units>Score on the scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".014" lower_limit="-.134" upper_limit=".166"/>
                    <measurement group_id="O2" value=".088" lower_limit="-.027" upper_limit=".203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire course of the study, from baseline to end of study period (min=26 days, max=239 days)</time_frame>
      <desc>weekly assessment by self-report and clinician review with patient</desc>
      <group_list>
        <group group_id="E1">
          <title>Methadone: Mothers</title>
          <description>Methadone
Methadone : daily oral dosing 20-140 mg</description>
        </group>
        <group group_id="E2">
          <title>Buprenorphine: Mothers</title>
          <description>Buprenorphine
Buprenorphine : sl daily 2-32 mg</description>
        </group>
        <group group_id="E3">
          <title>Methadone: Neonates</title>
          <description>Neonates born to mothers maintained on methadone</description>
        </group>
        <group group_id="E4">
          <title>Buprenorphine: Neonates</title>
          <description>Neonates born to mothers maintained on buprenorphine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sexually transmitted diseases</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>sleep disturbances</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abnormal fetal health</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>obstetrical</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Illicit drug use</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>psychological</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>psychosocial</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>postsurgical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood-borne disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>hematopoietic or lymphatic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>eye, ear, nose, or throat problems</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>endocrinologic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal laboratory values</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>dental problems</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>other AE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sexually transmitted diseases</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuromuscular</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>neurological</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>sleep disturbances</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>somatic</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abnormal fetal health</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>obstetrical</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Illicit drug use</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>psychological</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin conditions</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>psychosocial</sub_title>
                <description>Mothers only</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>postsurgical</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hendree Jones</name_or_title>
      <organization>Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, Johns Hopkins University School of Medicine</organization>
      <phone>919-485-2664</phone>
      <email>hjones18@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

